FDA Updates Earlier Guidance on Respiratory Treatment Spiriva HandiHaler The |

« FDA Unveils First Phase of Transparency Initiative The U.S. Food | Main | FDA Approves New Drug for Rheumatoid Arthritis The U.S. Food »

FDA Updates Earlier Guidance on Respiratory Treatment Spiriva HandiHaler The

FDA Updates Earlier Guidance on Respiratory Treatment Spiriva HandiHaler
The U.S. Food and Drug Administration today announced that data from a recent review of the Spiriva HandiHaler, a long-acting respiratory treatment for chronic obstructive pulmonary disease (COPD), do not support an increased risk of stroke, heart attack, or death in patients using the medicine.

Additional information in: FDA Recalls